MapLight Therapeutics (MPLT) Preferred Stock Liabilities (2024 - 2025)
MapLight Therapeutics (MPLT) reported Preferred Stock Liabilities of $198.9 million for Q3 2025, up 1145.82% on a YoY basis from $16.0 million in Q3 2024, and down 11.61% sequentially from $225.0 million in Q4 2024.
MapLight Therapeutics (MPLT) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Preferred Stock Liabilities data on file, last reported at $198.9 million in Q3 2025.
- For the quarter ending Q3 2025, Preferred Stock Liabilities rose 1145.82% year-over-year to $198.9 million; the trailing twelve-month figure through Sep 2025 stood at $198.9 million (up 1145.82% YoY), and the FY2024 full-year result was $225.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $198.9 million in Q3 2025, from $225.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $225.0 million in Q4 2024 to a low of $16.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 198.87 Mn |
| Dec 31, 2024 | 224.99 Mn |
| Sep 30, 2024 | 15.96 Mn |